2030-66-2

Basic information

• Product Name: (2Z)-heptan-2-one thiosemicarbazone
• CAS NO: 2030-66-2
• Molecular Formula: C₈H₁₇N₃S
• Molecular Weight: 187.3057
• Mol File: 2030-66-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 283.9°C at 760 mmHg
• Flash Point: 125.5°C
• Density: 1.07g/cm³
• Vapor Pressure: 0.00307mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: (2Z)-heptan-2-one thiosemicarbazone(CAS DataBase Reference)
• NIST Chemistry Reference: (2Z)-heptan-2-one thiosemicarbazone(2030-66-2)
• EPA Substance Registry System: (2Z)-heptan-2-one thiosemicarbazone(2030-66-2)

Safety Data

• Hazardous Substances Data: 2030-66-2(Hazardous Substances Data)

Usage

General Description

The chemical (2Z)-heptan-2-one thiosemicarbazone, also known as HHT, is a compound that has been studied for its potential medicinal properties. It is a thiosemicarbazone derivative, which means it contains a sulfur atom bonded to a carbon atom within its chemical structure. Thiosemicarbazones have been investigated for their anti-cancer, anti-viral, and anti-bacterial activities, making them potentially useful in the development of new drugs. HHT specifically has shown promise as an anti-cancer agent, with studies demonstrating its ability to inhibit the growth of cancer cells and induce apoptosis. Additionally, HHT has also been found to have anti-inflammatory properties, making it a compound of interest for further research in the field of medicinal chemistry.

Upstream product

• 110-43-0 n-pentyl methyl ketone 
• 79-19-6 thiosemicarbazide 

Downstream Products

• 1383114-67-7 1-(heptan-2-ylidene)-2-(4-(4-iodophenyl)thiazol-2-yl)hydrazine 
• 1448513-81-2 1-(heptan-2-ylidene)-2-(4-p-tolylthiazol-2-yl)hydrazine 
• 1448513-86-7 1-(heptan-2-ylidene)-2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazine 
• 1448513-98-1 1-(4-(2,4-dimethoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine 
• 1448514-09-7 1-(4-(2,4-dichlorophenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine 
• 1569467-31-7 1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine 
• 1623025-62-6 3-benzyl-2-(2-(heptan-2-ylidene)hydrazono)thiazolidin-4-one 

Relevant articles and documents

Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents

New 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives are proposed as dual-target-directed monoamine oxidase B (MAO-B) and acetylcholinesterase (AChE) inhibitors, as well as antioxidant agents, for the treatment of neurodegenerative disorders such as Parkinson's disease. Rational molecular design, target recognition and predicted pharmacokinetic properties have been evaluated by means of molecular modelling. Based on these properties, compounds were synthesized and evaluated in vitro as MAO-B and AChE inhibitors, and compared to the activities at their corresponding isozymes, monoamine oxidase A (MAO-A) and butyrylcholinesterase (BuChE), respectively. Anti-oxidant properties, potentially useful in the treatment of neurodegenerative disorders, have been also investigated in vitro. Among the evaluated compounds, three inhibitors may be considered as promising dual inhibitors of MAO-B and AChE, in vitro. MAO-B inhibition was also shown to be competitive and reversible for compound 19.

Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity

With reference to recent studies reporting on the various biological properties of the thiazolidinone scaffold, we synthesized more than a hundred compounds characterized by a 1,3-thiazolidin-4-one nucleus derivatised at the C2 with a hydrazine bridge linked to (cyclo)aliphatic or hetero(aryl) moieties, and their N-benzylated derivatives. These molecules were assayed as potential anti-Candida agents and they were shown to possess comparable, and in some cases higher biological activity than well-established topical and systemic antimycotic drugs (i.e. clotrimazole, fluconazole, ketoconazole, miconazole, tioconazole, amphotericin B). Compounds endowed with the lowest MICs underwent further testing in order to assess their cytotoxic effect (CC50) on Hep2 cells, which demonstrated their relative safety. Finally, QSAR and 3-D QSAR models were used to predict putative chemical modifications of the 1,3-thiazolidin-4-one scaffold in order to design new and potential more active compounds against Candida spp.

Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma

Antimitotic agents are widely used in cancer chemotherapy but the numerous side effects and the onset of resistance limit their clinical efficacy. Therefore, with the purpose of discovering more selective and efficient anticancer agents to be administered alone or in combination with traditional drugs, we synthesized a large library of 1,3,4-thiadiazoline analogues, maintaining the pharmacophoric structure of an antiproliferative compound known as K858: this is a new inhibitor of kinesin Eg5, able to induce the mitotic arrest in colorectal cancer cells and in xenograft ovarian cancer cells. We screened 103 compounds to assess their antiproliferative activity on PC3 prostate cancer cell line. Two derivatives, compounds 32 (corresponding to K858) and 33, have shown to be the most effective against prostate tumor cells and also towards two melanoma cell lines (SK-MEL-5 and SK-MEL-28) at low micromolar concentrations, confirming the pharmacological activity of this scaffold and revealing the potential role of 1,3,4-thiadiazolines in the management of cancer.